

Corporate Presentation

Nasdaq: AYTU August 2022 Aytu BioPharma is a commercial-stage biopharmaceutical company focused on delivering novel patient solutions to complex pediatric-centric conditions while developing a pipeline addressing underserved rare, pediatric-onset diseases.



Company Overview



Revenue growth from established & expanded commercial portfolio

- 138% year-over-year revenue growth to \$66M in FY21
- Expanded product portfolio accelerates revenue trajectory to over \$90M (pro forma) for FY22
- **Core Rx brands** address complex conditions within large addressable markets





Late-stage rare disease program


- **AR101/Enzastaurin** Phase 3 ready, rare disease asset
- AR101 will be the first and only treatment for vascular Ehlers-Danlos Syndrome (VEDS) if approved
- Orphan Drug and Fast Track designation received from FDA
- Orphan Drug designation received in EU
- US and EU site contracting underway

Leverageable commercial infrastructure & capabilities

- Leverageable commercial infrastructure focused on serving complex patient journeys and enabling access
- Recently expanded, innovative patient access platform scalable for current and future products across therapeutic areas



Aytu Strategic Growth Drivers





Strong Sequential Revenue Growth Year-Over-Year*



*June 30 Fiscal Year-End



Commercial Portfolio & Growth Trajectory

Differentiated Brands Competing in Large Markets





Novel, Effective Way to Manage ADHD Symptoms

- Only orally-disintegrating amphetamine tablet approved by FDA
- Effective, consistent treatment lasting over twelve hours
- Indicated for patients six years of age and older

Proven, Rapid Effectiveness for ADHD Patients 6-17 Years Old

- Only orally-disintegrating methylphenidate tablet approved by FDA
- 61% improvement in ADHD symptoms at 1 hour
- Provides once daily dosing with the convenience of an ODT



Multi-vitamins plus fluoride Rx line containing novel L-methylfolate

- Most prescribed multivitamin + fluoride Rx brand in U.S.
- Provides a convenient, good tasting supplement for patients in non-fluoridated areas
- Contains 'body-ready' L-methylfolate to enable efficient folic acid metabolism



SOURCES: 1. Data on file. Aytu BioPharma, Inc. 2. Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66-74.

Core Products Demonstrating Growth




• Achieved 42-month TRx high – 3/2022




• Achieved 11-month TRx high – 3/2022




• Poly-Vi-Flor Chewables achieved alltime monthly TRx high – 3/2022



Historical TRx (1,000's)



Historical TRx (1,000's)






Aytu RxConnect An Innovative Rx Growth Driver Putting patients first


Aytu RxConnect is a proprietary, best-inclass patient access program that enables affordable, predictable, hassle-free patient access to Aytu Rx products

- ~1,000 pharmacies nationwide with 100% sales territory coverage
- Reduces prescriber hassles that physicians encounter when prescribing branded medications
- Offers prescribers and patients affordability, predictability and access to Aytu brands for 100% of commercially insured






RxConnect's Novel Design Uniquely Serves Patients & HCPs Navigating Complex Treatment Journeys





Consumer Health Division Growing Organically and from New Product Launches

- Growing, diverse commercial portfolio of OTC medicines, dietary supplements, and personal care products
- Differentiated products competing in large consumer health categories
- Sales growth driven via direct-to-consumer and e-commerce channels



Advancing a Pipeline of High-Value, De-Risked Assets


Two therapeutic candidates target a devastating pediatric-onset rare disease and severe, difficult-to-treat respiratory infections

Program	Molecule/Asset	Proof of Concept	Phase 1	Phase 2	Phase 3
AR101*	Enzastaurin Vascular Ehlers-Danlos Syndrome (VEDS)				
Healight	UV-A light endotracheal catheter Severe respiratory infections				



* Received Orphan Drug Designation and IND acceptance to proceed to registrational study by FDA December 2021; EU Orphan Designation received in February 2022; Fast Track Designation received by FDA in April 2022.

Vascular Ehlers-Danlos Syndrome (VEDS): A Rare, Genetic, **Pediatric-Onset Disease with No Approved Treatments**



PSEUDO

DISSECTION



VEDS patients are at significant risk

- Patient are at risk for spontaneous, catastrophic vascular events that occur throughout the vascular tree
- Half of VEDS patients die by the age of 50
- 25% of patients experience a major complication by the age of 20 and 80% of patients by the age of 40

VEDS is easily diagnosed

- VEDS patients inherit the COL3A1 mutation from one parent
- Patients are diagnosed by family history or physical findings
- Confirmatory diagnosis via genetic testing (>99% accuracy)



AR101/Enzastaurin: Potential to Become the First and Only Treatment for VEDS

AR101 (enzastaurin), a PKCβ inhibitor, returns Kaplan-Meier survival curves to normal

- Novel animal model from the lab of Dr. Hal Dietz implicates PKC/ERK pathway in VEDS and demonstrates effectiveness of enzastaurin in preventing VEDS-related arterial events
- Exclusive global license to method of use patents provides broad protection beyond ODD

FDA agreed to a single pivotal trial \rightarrow urgent unmet need in a serious rare disease

- IND accepted by FDA December 2021 \rightarrow CMC, safety database, and clinical endpoints de-risked
- Orphan Drug designation granted December 2021 \rightarrow Fast Track designation granted April 2022
- Pivotal **PREVEnt Trial** underway with patient enrollment beginning in early 2023

Significant market potential


- ~16,000 VEDS patients globally and orphan pricing = \$1B Market Opportunity
- Orphan Drug market exclusivity for 7 years in US; 10 years in EU
- Potential for life cycle management in adjacent connective tissue disorders (e.g. Marfan Syndrome, Loeys-Dietz Syndrome)




Downregulation of PKC Signaling by AR101/Enzastaurin Decreases VEDS-Related Aortic Events

In animal models, COL3A1 mutations resulted in increased PKC/ERK signaling.

 $PKC\beta$ inhibition significantly prevented death due to spontaneous aortic rupture.







On Balance, the AR101 (Enzastaurin) Program in VEDS is De-risked Across Critical Gating Elements

Safety & Toxicity:

- ☑ Full battery of non-clinical safety and toxicity completed
- ☑ 66 clinical trials with 3,460 patients exposed to enzastaurin
- Phase 3 PRELUDE trial in DLBCL patients taking 500mg QD monotherapy for up to three years

PK Profile & Target Engagement:

PK model with 18,501 valid concentration measurements demonstrating target suppression

Regulatory Pathway:

- Study May Proceed Letter from the FDA and EU Scientific Advice Meeting
- Single pivotal trial agreed upon with the FDA and EMA

Manufacturing:

- ✓ Clinical trial material batched have been made
- Commercial supply has been scaled

Community Engagement:

- ☑ Trial sites have been identified
- Patient advocacy organizations engaged
- **Efficacy**:
 - □ Last remaining question will be addressed in the registrational PREVEnt Trial



Overview of the PREVEnt Trial in VEDS



Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome

Timelines

 Interim readout upon 50% of events (~18 months post first patient)

Primary Endpoint


• Time to intervention for arterial events

Secondary Endpoints

- Rate of intestinal rupture, pneumothorax, and retinal detachment
- Safety and tolerability

260 Patients


- With COL3A1 mutation
- Ages 18 to 60
- Plus, small number of ages 12 to 17




Registrational study expected to begin enrollment in early 2023



Healight[™] - Potential First-in-Class Treatment for Difficult-to-Treat Respiratory Conditions in Hospitalized Patients





Digital rendering of investigational Healight device insertion through ventilation tube of intubated patient

- UV-light based antimicrobial respiratory catheter licensed globally from Cedars-Sinai Medical Center
 - In vitro and in vivo studies demonstrate broad antimicrobial activity against a range of pathogens including coronavirus and pathogens causing ventilator-associated pneumonia (VAP)
- Patents filed in key markets globally first US patent granted 11/2021
- Positive COVID-19 clinical data from pilot study
 - Average log changes from baseline to day 5 and day 6 were -2.41 (>99%, p=0.0018) and -3.2 (>99.9%, p=0.0005), respectively
 - WHO clinical severity scores improved by an average of 1.6 and 3.6 points on day 15 and day 30, respectively
- Sham-controlled clinical trial evaluating 40 COVID-19 patients expected to get underway in Barcelona, Spain in mid-2022
- Positive pre-clinical VAP study results announced 4/2022; larger preclinical study now underway



SOURCES: U.S. patent number 11,179,575 issued 11/23/2021, Internal Ultraviolet Therapy, Rezaie, et al.; Leite et al. Ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with Coronavirus, *Photodiagnosis and Photodynamic Therapy*, September 2021. Leite et al., Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells via cell-cell signaling, *Journal of Photochemistry and Photobiology B: Biology*. In progress. February 2022.



Financials and Corporate Summary

Pro Forma Capitalization and Balance Sheet Summary

~\$27.6M cash balance as of March 31, 2022 \$15M of senior debt maturing February 2025

Aytu Capital Structure as of March 31, 2022 (in thousands)					
Common Stock Outstanding	33,355				
Outstanding Warrants and Equity Awards (1)	11,310				
Principal on senior secured debt (February 2025 maturity)	15,000				
Short term line of credit (March 31, 2022)	3,385				
Cash and Cash Equivalents (March 31, 2022)	\$27,613				

(1) Includes outstanding: pre-funded warrants (3,030,000), warrants (8,041,253), employee equity awards (238,345). Pre-funded warrants exercised in full in April 2022





Thank You